A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT ID: NCT06544616

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

498 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-22

Study Completion Date

2034-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preclinical Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: JNJ-64042056

Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 until Week 180.

Group Type EXPERIMENTAL

JNJ-64042056

Intervention Type DRUG

JNJ-64042056 will be administered intramuscularly.

Arm B: Placebo

Participants will receive IM injection of placebo from Week 0 until Week 180.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered intramuscularly.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-64042056

JNJ-64042056 will be administered intramuscularly.

Intervention Type DRUG

Placebo

Placebo will be administered intramuscularly.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elevated brain tau pathology defined as Braak 3 region of interest standardized uptake value ratio (ROI SUVR) greater than (\>) 1.1 (or equivalent based on emerging data) on a screening tau PET scan, reviewed centrally by a qualified reader to enrich for probability of disease progression during the study
* Clinical Dementia Rating (CDR) global score of 0 at screening and baseline
* Mini Mental State Examination (MMSE) greater than or equal to (\>=) 27 (with educational adjustment) at screening
* Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
* A participant must be of non-childbearing potential

Exclusion Criteria

* History consistent with or known autosomal dominant AD (mutation identified in the family and/or participant)
* Fulfills diagnostic criteria for Alzheimer's Dementia or non-Alzheimer's Dementia, including, but not limited to Frontotemporal Dementia (FTD), Diffuse Lewy Body Dementia (DLBD), Vascular Dementia (VAD), alcoholic dementia, Parkinson's dementia, Korsakov, Creutzfeldt-Jakob or other prion diseases, Posterior Cortical Atrophy
* Diagnosis of Mild Cognitive Impairment (MCI)
* Vitamin B12 or folate levels below the central laboratory lower limit of normal, unless the investigator determines that supplementation is not required after randomization
* History of or current neurological disease other than preclinical AD that may make interpretation of possible new neurological signs or symptoms difficult
Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Pharmaceutica N.V., Belgium Clinical trial

Role: STUDY_DIRECTOR

Janssen Pharmaceutica N.V., Belgium

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xenoscience Inc.

Phoenix, Arizona, United States

Site Status RECRUITING

Irvine Clinical Research

Irvine, California, United States

Site Status RECRUITING

Esperanza Clinical

Murrieta, California, United States

Site Status RECRUITING

Artemis Institute for Clinical Research

Riverside, California, United States

Site Status RECRUITING

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status RECRUITING

Yale University School Of Medicine

New Haven, Connecticut, United States

Site Status RECRUITING

JEM Research LLC

Atlantis, Florida, United States

Site Status RECRUITING

Excel Medical Clinical Trials, LLC

Boca Raton, Florida, United States

Site Status RECRUITING

K2 Medical Research Winter Garden

Clermont, Florida, United States

Site Status RECRUITING

Clinical NeuroScience Solutions Inc

Jacksonville, Florida, United States

Site Status RECRUITING

K2 Medical Research

Lady Lake, Florida, United States

Site Status RECRUITING

K2 Medical Research

Maitland, Florida, United States

Site Status RECRUITING

Merritt Island Medical Research, LLC

Merritt Island, Florida, United States

Site Status RECRUITING

Headlands Research Orlando

Orlando, Florida, United States

Site Status RECRUITING

Alzheimers Research and Treatment Center

Stuart, Florida, United States

Site Status RECRUITING

K2 Medical Research

Tampa, Florida, United States

Site Status RECRUITING

Charter Research

The Villages, Florida, United States

Site Status RECRUITING

Alzheimers Research and Treatment Center

Wellington, Florida, United States

Site Status RECRUITING

Palm Beach Neurology and Premier Research Institute

West Palm Beach, Florida, United States

Site Status RECRUITING

Great Lakes Clinical Trials

Chicago, Illinois, United States

Site Status RECRUITING

Great Lakes Clinical Trials

Gurnee, Illinois, United States

Site Status COMPLETED

Quest Research Institute

Farmington Hills, Michigan, United States

Site Status RECRUITING

Hattiesburg Clinic

Hattiesburg, Mississippi, United States

Site Status RECRUITING

The Cognitive and Research Center of New Jersey LLC

Springfield, New Jersey, United States

Site Status RECRUITING

Neurological Associates of Albany, PC

Albany, New York, United States

Site Status RECRUITING

Velocity Clinical Research

East Syracuse, New York, United States

Site Status RECRUITING

The Medical Research Network, LLC

New York, New York, United States

Site Status RECRUITING

AMC Research, LLC

Matthews, North Carolina, United States

Site Status RECRUITING

Valley Medical Research

Centerville, Ohio, United States

Site Status RECRUITING

Keystone Clinical Studies LLC

Plymouth Meeting, Pennsylvania, United States

Site Status RECRUITING

Butler Hospital

Providence, Rhode Island, United States

Site Status RECRUITING

Clinical Trials of Texas Inc

San Antonio, Texas, United States

Site Status RECRUITING

Memory Clinic Inc

Bennington, Vermont, United States

Site Status RECRUITING

University of Virginia

Charlottesville, Virginia, United States

Site Status RECRUITING

Neuro Trials Victoria

Carlton, , Australia

Site Status RECRUITING

The Prince Charles Hospital

Chermside, , Australia

Site Status RECRUITING

St Vincent's Centre for Applied Medical Research

Darlinghurst, , Australia

Site Status RECRUITING

Austin Health Heidelberg Repatriation Hospital

Ivanhoe, , Australia

Site Status RECRUITING

Southern Neurology

Kogarah, , Australia

Site Status RECRUITING

KaRa Institute of Neurological Diseases

Macquarie Park, , Australia

Site Status RECRUITING

Australian Alzheimer's Research Foundation Incorporated

Nedlands, , Australia

Site Status RECRUITING

Hopital Roger Salengro - CHU Lille

Lille, , France

Site Status RECRUITING

Hopital Nord Laennec CHU NANTES

Nantes, , France

Site Status RECRUITING

Hopital Lariboisiere-Fernand Widal

Paris, , France

Site Status RECRUITING

CHU Pitie Salpetriere

Paris, , France

Site Status RECRUITING

CHU Toulouse - Hôpital La Grave

Toulouse, , France

Site Status RECRUITING

CHRU Tours Hopital Bretonneau

Tours, , France

Site Status RECRUITING

Universitaetsklinikum der RWTH Aachen

Aachen, , Germany

Site Status RECRUITING

Universitaetsklinikum Koeln

Cologne, , Germany

Site Status RECRUITING

Universitaetsklinikum des Saarlandes

Homburg, , Germany

Site Status RECRUITING

Universitatsklinikum Munster

Münster, , Germany

Site Status RECRUITING

Enomoto Internal Medicine Clinic

Chofu-shi, , Japan

Site Status RECRUITING

Tokyo Asbo Clinic

Chūōku, , Japan

Site Status RECRUITING

Hatsuta Neurology Clinic

Hirakata-shi, , Japan

Site Status RECRUITING

Kobe City Medical Center General Hospital

Kobe, , Japan

Site Status RECRUITING

Kusunoki Clinic

Kobe, , Japan

Site Status RECRUITING

Musashimurayama Hospital

Musashimurayama, , Japan

Site Status RECRUITING

Saiseikai Narashino Hospital

Narashino-shi, , Japan

Site Status RECRUITING

ToCROM Clinic

Shinjuku Ku, , Japan

Site Status RECRUITING

Higashi-Shinjuku Clinic

Shinjuku-ku, , Japan

Site Status RECRUITING

Medical corporation Shinanokai Samoncho Clinic

Shinjyuku Ku, , Japan

Site Status RECRUITING

OCROM Clinic

Suita Shi, , Japan

Site Status RECRUITING

Nagomi Clinic

Toyonaka-shi, , Japan

Site Status RECRUITING

Jinsenkai MI Clinic

Toyonaka-shi, , Japan

Site Status RECRUITING

Barcelona Beta Brain Research Center

Barcelona, , Spain

Site Status RECRUITING

Fund. Ace-Inst. Cat. Neuroc. Aplicades

Barcelona, , Spain

Site Status RECRUITING

Hosp Clinic de Barcelona

Barcelona, , Spain

Site Status RECRUITING

Centro At. Esp. Oroitu

Getxo, , Spain

Site Status RECRUITING

Hosp. Univ. Santa Maria

Lleida, , Spain

Site Status RECRUITING

Hosp. Clinico San Carlos

Madrid, , Spain

Site Status RECRUITING

Clinica Univ. de Navarra

Pamplona, , Spain

Site Status RECRUITING

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, , Spain

Site Status RECRUITING

Idc Salud Hosp. Gral. de Catalunya

Sant Cugat del Vallès, , Spain

Site Status RECRUITING

Hosp. Mutua Terrassa

Terrassa, , Spain

Site Status RECRUITING

Hosp. Viamed Montecanal

Zaragoza, , Spain

Site Status RECRUITING

Skanes universitetssjukhus

Malmo, , Sweden

Site Status RECRUITING

Karolinska Universitetssjukhuset Huddinge

Stockholm, , Sweden

Site Status RECRUITING

Royal United Hospital

Bath, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

Birmingham, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

Bristol, , United Kingdom

Site Status RECRUITING

Scottish Brain Sciences

Edinburgh, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

Guildford, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

London, , United Kingdom

Site Status RECRUITING

Kings College Hospital

London, , United Kingdom

Site Status RECRUITING

University of Oxford

Oxford, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

Plymouth, , United Kingdom

Site Status RECRUITING

Moorgreen Hospital Memory Assessment And Research Centre

Southampton, , United Kingdom

Site Status RECRUITING

Southampton General Hospital

Southampton, , United Kingdom

Site Status RECRUITING

Re-Cognition Health

Winchester, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia France Germany Japan Spain Sweden United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Contact

Role: CONTACT

Phone: 844-434-4210

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

64042056ALZ2001

Identifier Type: OTHER

Identifier Source: secondary_id

2023-505096-68-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

64042056ALZ2001

Identifier Type: -

Identifier Source: org_study_id